Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562607 | 0.89 | NOTUM (0.41) | HPGDHSP90B1MAPK1NOTUMLMNA | |
| SCHEMBL2023955 | 0.85 | KMT2A (0.40) | HPGDLMNASMN1; SMN2TSHRMEN1 | |
| SCHEMBL5787779 | 0.84 | NOTUM (0.43) | HPGDHSP90B1NOTUMLMNAGPR35 | |
| SCHEMBL18298430 | 0.83 | MAPT (0.39) | HPGDHSP90B1LMNASMN1; SMN2MEN1 | |
| SCHEMBL29400731 | 0.82 | CYP3A4 (0.45) | HPGDNOTUMTSHRMEN1KMT2A | |
| SCHEMBL1104456 | 0.82 | CYP3A4 (0.45) | HPGDNOTUMTSHRMEN1KMT2A | |
| SCHEMBL21237481 | 0.82 | LMNA (0.36) | HPGDHSP90B1MAPK1NOTUMLMNA | |
| SCHEMBL22532078 | 0.81 | NOTUM (0.36) | HPGDHSP90B1NOTUMLMNATSHR | |
| SCHEMBL18786916 | 0.81 | NOTUM (0.40) | MAPK1NOTUMLMNAGPR35TSHR | |
| SCHEMBL2021932 | 0.81 | HDAC1 (0.40) | NOTUMSMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | CACCIOLA JOSEPH | 2010-12-23 | — | — | US | claimed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-115611883-B | PI3K alpha inhibitor with double-ring structure, and preparation method and application thereof | 生物岛实验室 | 2025-03-28 | — | — | CN | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| CN-114258393-B | Heterocyclic compounds having dual inhibitory activity of phosphatidylinositol 3-kinase delta and gamma and medical uses thereof | 中国医药研究开发中心有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024191714-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC | 2024-09-19 | — | — | US | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| CN-101309905-A | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2008-11-19 | — | — | CN | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | HPGD 1163/4885HSP90B1 1268/4885MAPK1 104/4885 |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | PDE3A, PDE3B, PDE5A | HPGD 418/4885HSP90B1 1233/4885MAPK1 2168/4885 |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | HPGD 1135/4885HSP90B1 3785/4885MAPK1 2286/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | HPGD 1421/4885HSP90B1 3474/4885MAPK1 2346/4885 |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | GRM1, GRM3, GRM2 | HPGD 2163/4885HSP90B1 4219/4885MAPK1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.